(Reuters) - Drugmaker XenoPort Inc and partner GlaxoSmithKline Plc said the U.S. Food and Drug Administration had approved their drug to treat shingles-related nerve pain. However, XenoPort's shares fell as much as 13 percent on concerns that a contractual dispute between Xenoport and GSK over the drug, Horizant, could now take longer to resolve, RBC Capital analyst Michael Yee said. The two partners are in a legal battle after XenoPort alleged that GSK had breached a contractual obligation.
Thu Jun 7, 2012 1:32pm EDT
Click here to read the whole story
Return to GoPath by clicking back arrow on the webpage